NASDAQ:RANI Rani Therapeutics (RANI) Stock Price, News & Analysis $0.56 -0.02 (-3.71%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.56 +0.01 (+1.13%) As of 05/30/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rani Therapeutics Stock (NASDAQ:RANI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rani Therapeutics alerts:Sign Up Key Stats Today's Range$0.55▼$0.6050-Day Range$0.48▼$1.4352-Week Range$0.46▼$5.67Volume135,940 shsAverage Volume807,653 shsMarket Capitalization$32.06 millionP/E RatioN/ADividend YieldN/APrice Target$9.40Consensus RatingBuy Company OverviewRani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Read More… Rani Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreRANI MarketRank™: Rani Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 638th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingRani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRani Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Rani Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rani Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rani Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.90% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Rani Therapeutics has recently increased by 25.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.90% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Rani Therapeutics has recently increased by 25.11%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.46 News SentimentRani Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.Search Interest10 people have searched for RANI on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows2 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.42% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.19% of the stock of Rani Therapeutics is held by institutions.Read more about Rani Therapeutics' insider trading history. Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RANI Stock News HeadlinesRani Therapeutics announces annual meeting resultsMay 30 at 9:12 PM | investing.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Average PT from AnalystsMay 27, 2025 | americanbankingnews.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 31, 2025 | Crypto 101 Media (Ad)Q3 Earnings Forecast for RANI Issued By Zacks Small CapMay 23, 2025 | americanbankingnews.comBrokers Offer Predictions for RANI Q2 EarningsMay 23, 2025 | americanbankingnews.comRani Therapeutics strikes deal to issue new warrantsMay 21, 2025 | uk.investing.comRANI: 1Q:25 Financial ResultsMay 20, 2025 | finance.yahoo.comRani Therapeutics Announces Research Agreement with ChugaiMay 19, 2025 | globenewswire.comSee More Headlines RANI Stock Analysis - Frequently Asked Questions How have RANI shares performed this year? Rani Therapeutics' stock was trading at $1.37 at the beginning of the year. Since then, RANI stock has decreased by 59.3% and is now trading at $0.5577. View the best growth stocks for 2025 here. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announced its earnings results on Tuesday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.22). The firm had revenue of $0.20 million for the quarter. When did Rani Therapeutics IPO? Rani Therapeutics (RANI) raised $100 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are Rani Therapeutics' major shareholders? Top institutional shareholders of Rani Therapeutics include Kestra Private Wealth Services LLC (0.24%), CWA Asset Management Group LLC (0.14%) and King Luther Capital Management Corp (0.10%). Insiders that own company stock include South Cone Investments Limited, Talat Imran, Mir A Imran, Kate Mckinley and Cortes Isidoro Alfonso Quiroga. View institutional ownership trends. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rani Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and Coca-Cola (KO). Company Calendar Last Earnings5/13/2025Today5/31/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RANI CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$9.40 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,585.5%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-219.64% Return on Assets-56.71% Debt Debt-to-Equity Ratio2.34 Current Ratio1.60 Quick Ratio1.60 Sales & Book Value Annual Sales$1.20 million Price / Sales26.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book1.09Miscellaneous Outstanding Shares57,482,000Free Float26,754,000Market Cap$32.06 million OptionableOptionable Beta0.25 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:RANI) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.